B. Metzler seel. Sohn & Co. AG Purchases New Holdings in Kymera Therapeutics, Inc. $KYMR

Key Points

• 15,607 shares bought: B. Metzler seel. Sohn & Co. AG purchased a new stake of 15,607 Kymera shares (≈$1.21M) and other institutions also increased positions, indicating renewed institutional interest.
• Insider selling is notable: insiders sold 350,734 shares (~$29.8M) over the last 90 days, including COO Jeremy Chadwick's 91,250‑share sale, which could weigh on sentiment despite some trades being 10b5‑1.
• Clinical catalyst vs. near‑term risk: the FDA granted Fast Track designation to KT‑621 (positive), and analysts have a consensus "Moderate Buy" with a ~$118.90 target, but Kymera recently missed quarterly revenue/EPS and will report Q1 results on April 30, adding event-driven volatility risk.

B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,607 shares of the company's stock, valued at approximately $1,214,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Bessemer Group Inc. increased its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after acquiring an additional 815 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Kymera Therapeutics during the second quarter valued at approximately $73,000. Finally, US Bancorp DE increased its position in shares of Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company's stock valued at $106,000 after acquiring an additional 166 shares during the last quarter.

Insider Transactions at Kymera Therapeutics

In other news, insider Noah Goodman sold 8,264 shares of the firm's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $87.50, for a total value of $723,100.00. Following the completion of the transaction, the insider directly owned 53,542 shares of the company's stock, valued at $4,684,925. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jeremy G. Chadwick sold 91,250 shares of the firm's stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total value of $7,063,662.50. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares of the company's stock, valued at $4,737,646.82. The trade was a 59.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 350,734 shares of company stock valued at $29,758,502. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: FDA granted Fast Track designation to KT‑621 (oral STAT6 degrader) for eosinophilic asthma — accelerates development pathway and can increase regulatory interaction and potential commercial value if clinical data remain positive. FDA Fast Track for KT-621
• Positive Sentiment: Strong analyst and institutional support — multiple recent buy/outperform ratings and a median analyst target near $120, plus large institutional additions reported in recent quarters, provide a bullish backdrop for longer-term upside. Quiver / Analyst & Institutional Snapshot
• Neutral Sentiment: Company will report Q1 2026 results and host a webcast on April 30 — an upcoming earnings call adds near‑term event risk and potential for volatility depending on guidance, cash burn and clinical spend details. Q1 2026 Results Announcement
• Neutral Sentiment: Short interest data reported appears to be a data anomaly (shows 0 shares / NaN change) — not meaningful for positioning until corrected by exchanges/data providers.
• Negative Sentiment: Recent insider sales: COO Jeremy Chadwick sold 300 shares (~$90 each) and Director Bruce Booth executed sales (including a 5,900‑share reduction) — while some trades were under pre‑arranged 10b5‑1 plans, continued insider selling can pressure sentiment. Chadwick Insider Sale Booth Form 4 (10b5-1)
• Negative Sentiment: Broad pattern of insider selling over the past 6 months (many executive sales and relatively few purchases) increases perception of near‑term distribution risk despite institutional buying. Quiver Insider Trading Summary

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $84.91 on Monday. The business has a fifty day simple moving average of $84.63 and a two-hundred day simple moving average of $75.76. Kymera Therapeutics, Inc. has a 1 year low of $28.06 and a 1 year high of $103.00. The company has a market capitalization of $6.93 billion, a P/E ratio of -23.07 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to analysts' expectations of $14.80 million. During the same period in the prior year, the business earned ($0.88) earnings per share. The business's quarterly revenue was down 60.8% compared to the same quarter last year. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on KYMR. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Barclays raised their target price on Kymera Therapeutics to $133.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 27th. BTIG Research decreased their target price on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Jefferies Financial Group began coverage on Kymera Therapeutics in a research report on Monday, March 16th. They issued a "buy" rating and a $110.00 target price for the company. Finally, Citigroup raised their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.